Precautions for use of tilpotide/tilsiparatide (Mufenda) and safety guide for daily medication

Tirzepatide (Tirzepatide) is a dual insulin secretion receptor agonist that acts on both GIP and GLP-1 receptors. It is currently mainly used for the treatment of type 2 diabetes and has received widespread attention for its significant weight management effect. The drug achieves dual effects of hypoglycemia and weight loss by enhancing glucose-dependent insulin secretion, inhibiting glucagon release, delaying gastric emptying and reducing appetite. Because of its comprehensive mechanism of action, special attention needs to be paid to medication specifications and safety management during use.

Before initiating tilpotide, patients should receive a complete medical evaluation, including past medical history, history of pancreatic disease, gastrointestinal disease, and the presence of thyroid-related disease. This drug is generally not recommended for people with a family history of medullary thyroid cancer or multiple endocrine neoplasia syndrome. In addition, pregnant and lactating women and patients with severe gastrointestinal motility disorders also need to carefully evaluate the risks and benefits before use.

Tilpotide is usually administered by subcutaneous injection once a week, emphasizing the principle of "initiating at a low dose and gradually increasing it". Using a lower dose in the initial stage can help reduce gastrointestinal adverse reactions such as nausea, vomiting, and bloating. Dosage adjustments should be made strictly in accordance with the doctor's recommendations. It is not advisable to increase the dosage or shorten the dosing interval on your own, otherwise it may increase the probability of hypoglycemia or intolerance reactions.

In terms of daily medication safety, patients need to pay special attention to gastrointestinal reactions, which are the most common adverse reactions of tilpotide. In the early stage of medication, you should pay attention to small meals and frequent meals, and avoid high-fat and high-sugar diets to reduce nausea and abdominal discomfort. If persistent vomiting, severe abdominal pain or suspected symptoms of pancreatitis occur, the drug should be discontinued immediately and seek medical treatment instead of self-observation or continued injections.

Patients taking other antidiabetic drugs concomitantly, especially insulin or sulfonylureas, need to be alert to the risk of hypoglycemia. Although tilpotide itself is less likely to cause hypoglycemia, hypoglycemia may still occur when used in combination. It is recommended that patients regularly monitor fasting and postprandial blood sugar, and promptly replenish sugar and report to their doctor when symptoms of hypoglycemia such as palpitation, sweating, and hand shaking occur.

In terms of weight management, Tilpotide has an obvious weight loss effect, but it is not simply "you can lose weight just by taking medication". If you overeat or consume high calories for a long time during use, the weight loss effect will be significantly reduced, and weight rebound may even occur. Therefore, a reasonable diet structure, regular exercise and lifestyle intervention are still important foundations to ensure stable efficacy and long-term safety.

In general, Tirzepatide (Tirzepatide) is a drug with outstanding efficacy but high management requirements, and is suitable for standardized use under the long-term follow-up and guidance of doctors. Patients should pay attention to dose adjustment, blood sugar monitoring and adverse reaction observation, and should not stop medication or change the medication plan at will. Only by combining scientific medication with a healthy lifestyle can its clinical value in reducing blood sugar and weight loss be maximized while reducing potential medication risks.

Keyword tags: Tilpotide, precautions, gastrointestinal reactions, hypoglycemia, weight management, lifestyle

Reference materials:https://pubmed.ncbi.nlm.nih.gov/36251836/